Altimmune Q3 Loss Widens to $31.6M as MASH Phase 3 Spending Ramps; $494.9M Liquidity
ALT is trading near its 52-week low of $1.6 (3.1% above the low) on elevated volume (3.1× avg).
Summary
Altimmune's Q3 loss widened to $31.6 million ($0.15/share) on a 81% R&D jump, but $494.9 million of cash and investments plus the $10.0 million Hercules tranche keep the MASH Phase 3 program funded past twelve months. The April 2026 offering left 75 million warrants at a $3.00 strike outstanding.
Key Events · Earnings and Guidance · ALT
-
Q3 Loss Widens on Trial Spending
Net loss of $31.6 million ($0.15/share) versus $19.0 million a year ago, driven by R&D of $27.0 million (up 81%) and G&A of $8.7 million (up 47%).
-
Liquidity of $494.9 Million
$28.9 million cash, $236.2 million short-term investments and $214.8 million long-term investments at September 30, 2026; management says this funds operations for at least twelve months.
-
Hercules Tranche Three Drawn
On October 27, 2026 the company drew $10.0 million of Tranche Three, extending the interest-only period to June 1, 2028 and requiring qualified cash of at least 60% of term loan principal.
-
75 Million Warrants Overhang
April 2026 offering left 75,000,000 common stock warrants at a $3.00 strike plus 10,750,000 pre-funded warrants outstanding; full cash exercise would raise $225 million.
Analysis · ALT · Life Sciences
The Q3 loss of $31.6 million ($0.15/share) came in well above the $25.48 million consensus as R&D jumped 81% to $27.0 million on the PERFORMA Phase 3 MASH trial and the RESTORE ALD trial. More important than the P&L is the balance sheet: $494.9 million of cash and investments ($28.9M cash, $236.2M short-term, $214.8M long-term) funds operations for at least twelve months, and the October 27 draw of the $10.0 million Hercules Tranche Three pushed the interest-only period out to June 1, 2028. Against that, nine-month operating burn of $82.9 million is up $34.8 million year over year, and the April 2026 offering left 75,000,000 common warrants at a $3.00 strike outstanding — roughly 39% of the 194.5 million shares outstanding — a large overhang that only becomes cash if the stock more than doubles from today's $1.65.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALT was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $313.2M. The 52-week trading range was $1.60 to $6.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.